Clinical research

Retatrutide (TRIUMPH programme): Retatrutide phase 3 results

Phase 3 programme; the published phase 2 trial was randomised, double-blind and placebo-controlled. Sample size not extracted, over an unspecified duration. Sponsor: Eli Lilly and Company.

Retatrutide (TRIUMPH programme) (no registry ID on file) tested retatrutide, a glp-1, gip and glucagon triple receptor agonist against a comparator in adults with obesity, or overweight with weight-related complications. Unverified — no source on file: the source is a citable record we could not authoritatively link, which we have not independently re-extracted from the full paper in this session.

Study design

Results

Not extracted.

Adverse events & discontinuations

Not extracted from the source in this session.

Limitations

Retatrutide is investigational. It is not approved by the FDA or EMA for any indication, and it is not legally available from any telehealth provider or compounder.

Practical interpretation

This is one trial, reported by Eli Lilly and Company, read directly against the registry and publication linked below — GLP Ranked has not re-run the statistics or obtained the patient-level data. Results describe group averages under trial conditions and may not describe any individual's outcome, including with a compounded, non-FDA-approved version of a similar active ingredient. Always check the primary source before citing a specific number.